Mitchell Chan

Mitchell Chan is an experienced professional in the biotechnology and finance sectors, currently serving as a Board Member at Avalo Therapeutics and as a Director on the Board of Directors for the Maryland Tech Council. Previously, Mitchell held the position of Operating Partner at Catalio Capital Management and served as Chief Financial Officer and Vice President of Finance & Corporate Strategy at Viela Bio. Additionally, Mitchell worked as the Director of Investor Relations for North America at AstraZeneca. Educational qualifications include attendance at the University of California, Berkeley, Haas School of Business in 2015 and The Wharton School in 2016.